Abstract

A NOVEL LCZ696 DRUG THERAPY VERSUS ENALPRIL IN THE TREATMENT OF HEART FAILURE

Niraj Khatri Sapkota*

Abstract

LCZ696 (sacubitril valsartan) is a first-in-class angiotensin receptorneprilysin inhibitor that has been developed for the use of heartfailure correspondingly neprilysin is an enzyme that contributes to thebreakdown of the biologically active natriuretric vasodilator peptide(ANP) and several other vasoactive compounds. Neprilysin inhibitorhas been proved to be a therapeutic target for several compounds thathave been tested in cardiovascular disease. Although ecadotril,candoxatril, and omapatrilat were initially tested in hypertensionand/or heart failure, lack of efficacy and side effects led todiscontinuation of their development. LCZ696 is a compoundcomposed of 2 molecular moieties in a single crystalline complex, the angiotensin receptorblocker valsartan and a neprilysin inhibitor, pro-drug phase 2 trial in heart failure withpreserved ejection fraction which demonstrated greater efficacy than enalapril in a phase 3trial in heart failure with reduced ejection fraction, therefore LCZ696 posses superior efficacyin the management of heart failure compared to the enalpril by decreasing the rate ofmorbidity and mortality and its mechanism is to inhibit or suppress the renin- angiotensinaldosterone(RAAS) axis and augment the endogenous natriuretic peptide system.

Keywords: LCZ696,Neprilysin,Enalpril, Heart failure.